<DOC>
	<DOC>NCT00150748</DOC>
	<brief_summary>An open-label, follow-up study to evaluate the safety and efficacy of levetiracetam (LEV), in children (â‰¥ 4 years old), adolescents and adults suffering from primary generalized seizures.</brief_summary>
	<brief_title>Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsy, Generalized</mesh_term>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Male or female children, adolescents and adults having completed the final visit of a previous study with levetiracetam (LEV) Subjects who were/are suffering from primary generalized (type II) epileptic seizures Subjects for whom the Investigator believes a reasonable benefit (efficacy or tolerability) from the longterm administration of LEV may be expected Known clinically significant acute or chronic illness, for example: cardiac, renal or hepatic dysfunction, etc., which may impair reliable participation in the trial or necessitate the use of medication not allowed by protocol Concomitant use of any drug with possible central nervous system effects unless at a stable dose Concomitant use of any drug (other than hormonal treatment and the subject's normal antiepileptic drugs (AEDs) that may influence the metabolism of the concomitant AED(s), except if the dose has been stable before entry in the study for sufficient length of time</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Generalized Epilepsy, Primary Generalized Seizures</keyword>
	<keyword>Keppra, Levetiracetam</keyword>
</DOC>